(NP (NP (NN Pentoxifylline)) (PP (IN for) (NP (NP (DT the) (NN treatment)) (PP (IN of) (NP (NP (NN infection)) (PP (IN with) (NP (JJ human) (NN immunodeficiency) (NN virus))))))) (. .))
(S (NP-SBJ-1 (NP (NN Cytokine) (NN dysregulation)) (PP (IN in) (NP (NP (NP (JJ human) (NN immunodeficiency) (NN virus) (NN type) (CD 1)) (PRN (-LRB- -LRB-) (NP (NN HIV-1)) (-RRB- -RRB-))) (NN infection)))) (VP-COOD (VP (VBZ has) (VP (VBN been) (VP (VBN documented) (NP (-NONE- *-1)) (PP (IN in) (NP (JJ numerous) (NNS studies)))))) (CC and) (VP (VBZ has) (VP (VBN been) (VP (VBN cited) (NP (-NONE- *-1)) (PP (IN as) (NP (NP (DT an) (JJ important) (NN component)) (PP (IN in) (NP (NP (DT the) (NN pathogenesis)) (PP (IN of) (NP (DT this) (JJ retroviral) (NN infection))))))))))) (. .))
(S (NP-SBJ-3 (NP (JJ Pharmacological) (NN modification)) (PP (IN of) (NP (NN cytokine) (NN dysregulation)))) (, ,) (ADVP (RB therefore)) (, ,) (VP (VBZ has) (VP (VBN been) (VP (VBN suggested) (NP (-NONE- *-3)) (PP (IN as) (NP (NP (DT a) (JJ therapeutic) (NN modality)) (PP (IN for) (NP (NN HIV-1) (NN infection)))))))) (. .))
(S (NP-SBJ (NP (NNP Dr.) (NNP Dezube)) (PP (IN of) (NP (NP (NNP Beth) (NNP Israel) (NNP Hospital)) (PRN (-LRB- -LRB-) (NP (NNP Boston)) (-RRB- -RRB-))))) (ADVP (RB concisely)) (VP (VBZ reviews) (NP (NP (DT the) (NN state)) (PP (IN of) (NP (NP (PRP$ our) (NN knowledge)) (PP (VBG regarding) (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (NN pentoxifylline))) (PP (IN on) (NP (NP (NN expression)) (PP (IN of) (NP (NP (NN tumor) (NN necrosis) (NN factor-alpha)) (, ,) (NP (NP (DT a) (NN cytokine)) (VP (VBN known) (S (NP-SBJ (-NONE- *)) (VP-COOD (VP (TO to) (VP (VB influence) (NP (NN HIV-1) (NN replication)))) (CC and) (VP (TO to) (VP (VB play) (NP (DT a) (JJ possible) (NN role)) (PP (IN in) (NP (NP (DT the) (JJ clinical) (NNS manifestations)) (PP (IN of) (NP (NP (JJ advanced) (NN infection)) (PP (IN with) (NP (DT this) (NN virus))))))))))))))))))))))) (. .))
(S (NP-SBJ-4 (NP (NN Pentoxifylline)) (, ,) (NP (DT a) (JJ trisubstituted) (NN xanthine) (NN derivative)) (, ,)) (VP-COOD (VP (VBZ has) (VP (VBN been) (VP (VBN used) (NP-5 (-NONE- *-4)) (S (NP-SBJ (-NONE- *-5)) (VP (TO to) (VP (VB decrease) (NP (NN blood) (NN viscosity)))))))) (CC and) (VP (VBZ is) (VP (ADVP (RB reasonably) (RB well)) (VBN tolerated) (NP (-NONE- *-4)) (PP (IN by) (NP-LGS (NP (JJS most) (NNS recipients)) (PP (IN of) (NP (DT the) (NN drug)))))))) (. .))
(S (NP-SBJ (NP (NNS Results)) (PP (IN of) (NP (NP (JJ preliminary) (NNS studies)) (, ,) (SBAR (WHNP-7 (NP (JJ many)) (WHPP (IN of) (WHNP (WDT which)))) (S (NP-SBJ-8 (-NONE- *T*-7)) (VP (VBD were) (VP (VBN conducted) (NP (-NONE- *-8)) (PP (IN by) (NP-LGS (NNP Dr.))))))) (NNP Dezube)))) (VP (, ,) (SBAR (VBP suggest) (S (NP-SBJ (NP (IN that)) (PP (NN use) (NP (IN of) (DT this))) (PP (NN agent) (NP (NP (IN in)) (PP (NN combination) (NP (IN with) (JJ antiretroviral)))))) (VP (NNS compounds) (VP (MD may) (ADJP-PRD (VB prove) (PP (JJ useful) (NP (NP (IN in) (DT the)) (PP (NN treatment) (NP (NP (IN of)) (PP (NNS patients) (NP (IN with) (NN HIV-1))))))))))))) (NN infection))
